Calendar

Nov
13
Mon
2017 Russ Pitzer Lecture – J. Andrew McCammon @ 100 Stillman Hall
Nov 13 @ 4:10 pm – 5:10 pm

Lecturer: J. Andrew McCammon, University of California, San Diego

Title: Thermodynamics of Molecular Recognition

Light reception to follow in CBEC lobby

 

J. Andrew McCammon is the Joseph E. Mayer Chair Professor of Theoretical Chemistry and Distinguished Professor of Pharmacology at UCSD.   He received his B.A. from Pomona College, and his Ph.D. in chemical physics from Harvard University, where he worked with John Deutch (of MIT).  In 1976-78, he developed the computer simulation approach to protein dynamics in Martin Karplus’s lab at Harvard.  He joined the University of Houston as Assistant Professor of Chemistry in 1978, and became the M.D. Anderson Chair Professor of Chemistry in 1981. He moved to UCSD in 1995.  Professor McCammon has invented theoretical methods for accurately predicting and interpreting molecular recognition, rates of reactions, and other properties of chemical systems.  In addition to their fundamental interest, these methods play a growing role in the design of new drugs and other materials.  Professor McCammon is the author with Stephen Harvey of “Dynamics of Proteins and Nucleic Acids” (Cambridge University Press), and is the author or co-author of more than 800 publications in theoretical chemistry and biochemistry. More than 80 of his graduate students and postdoctoral fellows have secured tenured or tenure-track faculty positions at leading colleges and universities.  In the 1980’s, Professor McCammon guided the establishment of the computer-aided drug discovery program of Agouron Pharmaceuticals (now Pfizer Global Research and Development, La Jolla Laboratories), and contributed to the development of the widely prescribed HIV-1 protease inhibitor, Viracept (nelfinavir).  The McCammon group’s studies of HIV-1 integrase flexibility contributed to the discovery of the first in a new class of antiviral drugs by Merck & Co., named Isentress (raltegravir) and approved by the US FDA in 2007. Professor McCammon received the first George Herbert Hitchings Award for Innovative Methods in Drug Design from the Burroughs Wellcome Fund in 1987.  In 1995, he received the Smithsonian Institution’s Information Technology Leadership Award for Breakthrough Computational Science, sponsored by Cray Research.  He is the recipient of the American Chemical Society’s 2008 National Award for Computers in Chemical and Pharmaceutical Research.  He received the Joseph O. Hirschfelder Prize in Theoretical Chemistry for 2016-17 and the Russell M. Pitzer Award in Theoretical Chemistry in 2017. Professor McCammon is a Fellow of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, the American Physical Society, and the Biophysical Society.  He is a Member of the US National Academy of Sciences.

 

Nov
16
Thu
Devon Walter Meek Lecture – Dennis C. Liotta @ CBEC 130
Nov 16 @ 4:00 pm – 5:30 pm

Lecturer: Dennis C. Liotta

Affiliation: Emory University

 

Reception to follow in CBEC Lobby including an Undergraduate Poster Session and a Dow Graduate Student Poster Session.

 

Over the past two and a half decades Dr. Dennis Liotta’s research has focused on the discovery and development of novel antiviral, anticancer and anti-inflammatory therapeutic agents. He is recognized as one of the premier discoverers of novel therapeutics, having been one of the inventors associated with ten FDA approved therapeutics including Epivir, Combivir, Trizivir, Epzicom, Epivir-HBV, Emtriva, Truvada, Atripla, Complera and Stribid. In addition, he is the inventor of record for several clinically important antivirals, including Epivir, Reverset, Racivir and Elvucitabine. He is also the lead inventor of Q-122 (formerly known as MSX-122), a safe, orally available clinical agent for controlling hot flashes in post-menopausal women. In the preclinical arena his research group has recently discovered the first potent, dual tropic (CCR5/CXCR4) HIV entry inhibitor. In addition, in his current role as Executive Director of the Emory Institute for Drug Development, Dr. Liotta oversaw the discovery and development of a novel nucleoside analogue, EIDD-2023, for treating hepatitis C infections.

 

Dr. Liotta has authored over 250 peer reviewed publications and is an inventor on over 75 issued US patents. A company he founded, Pharmasset (acquired by Gilead Sciences) developed Sofosbuvir, which has become the first line therapy for treating (and perhaps curing) hepatitis C. In addition, he has founded numerous other companies including, inter alia: (a) Altiris (drugs for stem cell mobilization and as potential treatments for a variety of cancers); (b) Triangle Pharmaceuticals (developed emtricitabine and was subsequently acquired by Gilead Sciences); (c) NeurOp (therapies for treating ischemic conditions, such as stroke); (d) QUE Oncology, a joint venture owned by the University of Queensland and Emory, that is carrying out the Q-122 clinical trials (vide supra); and (e) DRIVE (Drug Innovation Ventures at Emory, a non-profit drug development company focused on the development of therapies for treating single stranded RNA virus infections, such as Dengue Fever, hepatitis C, influenza A and B, respiratory syncytial virus and various equine encephalitis viruses). DRIVE utilizes an innovative model that seeks to extract maximum value from therapeutic innovations discovered at Emory or elsewhere by efficiently advancing them into clinical trials.

Nov
17
Fri
Devon Walter Meek Lecture – Dennis C. Liotta @ CBEC 130
Nov 17 @ 4:10 pm – 5:30 pm

Lecturer: Dennis C. Liotta

Affiliation: Emory University

 

Reception to follow in CBEC Lobby including an Undergraduate Poster Session and a Dow Graduate Student Poster Session.

 

Over the past two and a half decades Dr. Dennis Liotta’s research has focused on the discovery and development of novel antiviral, anticancer and anti-inflammatory therapeutic agents. He is recognized as one of the premier discoverers of novel therapeutics, having been one of the inventors associated with ten FDA approved therapeutics including Epivir, Combivir, Trizivir, Epzicom, Epivir-HBV, Emtriva, Truvada, Atripla, Complera and Stribid. In addition, he is the inventor of record for several clinically important antivirals, including Epivir, Reverset, Racivir and Elvucitabine. He is also the lead inventor of Q-122 (formerly known as MSX-122), a safe, orally available clinical agent for controlling hot flashes in post-menopausal women. In the preclinical arena his research group has recently discovered the first potent, dual tropic (CCR5/CXCR4) HIV entry inhibitor. In addition, in his current role as Executive Director of the Emory Institute for Drug Development, Dr. Liotta oversaw the discovery and development of a novel nucleoside analogue, EIDD-2023, for treating hepatitis C infections.

 

Dr. Liotta has authored over 250 peer reviewed publications and is an inventor on over 75 issued US patents. A company he founded, Pharmasset (acquired by Gilead Sciences) developed Sofosbuvir, which has become the first line therapy for treating (and perhaps curing) hepatitis C. In addition, he has founded numerous other companies including, inter alia: (a) Altiris (drugs for stem cell mobilization and as potential treatments for a variety of cancers); (b) Triangle Pharmaceuticals (developed emtricitabine and was subsequently acquired by Gilead Sciences); (c) NeurOp (therapies for treating ischemic conditions, such as stroke); (d) QUE Oncology, a joint venture owned by the University of Queensland and Emory, that is carrying out the Q-122 clinical trials (vide supra); and (e) DRIVE (Drug Innovation Ventures at Emory, a non-profit drug development company focused on the development of therapies for treating single stranded RNA virus infections, such as Dengue Fever, hepatitis C, influenza A and B, respiratory syncytial virus and various equine encephalitis viruses). DRIVE utilizes an innovative model that seeks to extract maximum value from therapeutic innovations discovered at Emory or elsewhere by efficiently advancing them into clinical trials.

Nov
20
Mon
Analytical/Physical Seminar – Dr. Anna Krylov @ 2004 Evans Laboratory
Nov 20 @ 4:10 pm – 5:10 pm

Title: TBA

Affiliation: University of Southern California

Hosted by: Dr. Herbert

Dec
4
Mon
Analytical/Physical Seminar – Dr. Tom Greenbowe @ 2004 Evans Laboratory
Dec 4 @ 4:10 pm – 5:10 pm

Title: TBA

Affiliation: University of Oregon

Hosted by: Dr. Clark

Dec
11
Mon
Faculty Seminar – Dr. Robert Baker @ 1005 Smith Lab
Dec 11 @ 4:10 pm – 5:10 pm

Speaker: Dr. Robert Baker

Title: Ultrafast Charge Carrier Dynamics in Metal Oxide Catalysts

Mar
26
Mon
Analytical/Physical Seminar – Dr. Thomas Brunold @ 2004 Evans Laboratory
Mar 26 @ 4:10 pm – 5:10 pm

Title: TBA

Affiliation: University of Wisconsin, Madison

Hosted by: Dr. Shafaat

Apr
23
Mon
Analytical/Physical Seminar – Dr. Lars Konermann @ 2004 Evans Laboratory
Apr 23 @ 4:10 pm – 5:10 pm

Title: TBA

Affiliation: University of Western Ontario

Hosted by: Dr. Badu